ETNB 89bio, Inc. Quick Ratio

A bet on organic research development without mergers defines the cost structure of 89bio, Inc. (ETNB). The trend in the acid-test ratio demonstrates stable coverage of liabilities with cash, where the value of 14.80 serves as a baseline indicator of financial maturity. The high efficacy of pegozafermin in treating fibrosis and the massive MASH market create a solid foundation for the growth of the company's future cash flows.

This metric is calculated as the ratio of the most liquid assets (cash and accounts receivable) to current liabilities, excluding slow-moving inventories to assess real solvency. For the R&D company 89bio, Inc. (ETNB), which develops unique liver therapies, the quick ratio forecast is critically important as it demonstrates the ability to fund development prior to commercialization without resorting to expensive external capital.